Srdan Verstovsek, MD, on Predicting Resistance to Hydroxyurea Therapy in Polycythemia Vera

Srdan Verstovsek, MD, of the MD Anderson Cancer Center, speaks on a study that used machine learning to predict resistance to hydroxyurea therapy in patients with polycythemia vera. Dr. Verstovsek and colleagues presented the study’s results at the 2022 American Society of Hematology Annual Meeting.